22.00
-0.67 (-2.96%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Bicara Therapeutics Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | -1.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | -0.5 |
| Average | -2.00 |
|
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.65% |
| % Held by Institutions | 89.28% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Red Tree Management, Llc | 30 Jun 2026 | 3,163,517 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| COHLHEPP RYAN | - | 23.71 | -17,500 | -414,925 |
| Aggregate Net Quantity | -17,500 | |||
| Aggregate Net Value ($) | -414,925 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 23.71 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| COHLHEPP RYAN | Officer | 08 Sep 2026 | Automatic sell (-) | 17,500 | 23.71 | 414,925 |
| COHLHEPP RYAN | Officer | 08 Sep 2026 | Option execute | 17,500 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |